Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Zimmer Biomet Holdings Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.7× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| QQQE | ZBH | |
|---|---|---|
Market Cap | $1.45B | $16.95B |
Volume | 323,568 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $103.98 |
52-Week Low | $96.06 | $79.58 |
Typical Hold Time | 48 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.03, down 0.71% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Recent news highlights its equal-weight strategy reducing technology concentration compared to market-cap weighted peers. The fund provides diversified exposure to large-cap growth stocks within the Nasdaq-100 index.
The outlook for QQQE is supported by its tactical appeal as an equal-weight alternative, though it carries risks tied to Nasdaq performance and sector concentration. Investor sentiment appears cautiously optimistic given recent favorable coverage comparing it to QQQ. The absence of traditional valuation ratios is typical for an ETF tracking an index.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
